Table 3 Results of cost-effectiveness analyses, Bacteremia model
From: Risk-stratification in febrile infants 29 to 60 days old: a cost-effectiveness analysis
Cost ($) | Incremental Cost ($) | Effectiveness (QALY) | Incremental Effectiveness(QALY) | ICER ($/QALY) | |
|---|---|---|---|---|---|
PECARN | $3671 | – | 0.779 | – | – |
Boston | $3701 | $30 | 0.782 | 0.003 | $9799 |
Rochester | $3846 | $145 | 0.778 | −0.004 | Dominated |
Step-by-Step | $3977 | $276 | 0.778 | −0.004 | Dominated |
Clinical suspicion | $4430 | $729 | 0.764 | −0.019 | Dominated |
Aronson | $4527 | $826 | 0.782 | −0.001 | Dominated |
Modified Philadelphia | $4594 | $892 | 0.778 | −0.004 | Dominated |
Philadelphia | $4722 | $1021 | 0.781 | −0.001 | Dominated |